Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques

被引:37
作者
Tobery, TW
Smith, JF
Kuklin, N
Skulsky, D
Ackerson, C
Huang, LY
Chen, L
Cook, JC
McClements, WL
Jansen, KU
机构
[1] Merck Res Labs, Dept Virus & Cell Biol, West Point, PA 19486 USA
[2] Merck Res Labs, Dep Fermentat & Cell Culture, West Point, PA 19486 USA
关键词
human papillomavirus; vaccine; non-human primate;
D O I
10.1016/S0264-410X(02)00679-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There have been numerous studies to assess the immunogenicity of candidate therapeutic and prophylactic vaccines for human papillomavirus (HPV), but few of them have directly compared different vaccines in an immunologically relevant animal system. In the present study, several vaccine delivery systems (VLPs, chimeric VLPs, plasmid DNA, and a replication incompetent adenoviral vector) expressing HPV16L1 were evaluated for their ability to induce HPV16L1 VLP-specific humoral immune responses, including neutralizing antibodies, and cell-mediated immune responses in rhesus macaques. Monkeys immunized with HPV16L1 VLPs mounted a potent humoral response with strongly neutralizing antibodies and a strong L1-specific Th2 response as measured by IL-4 production by CD4+ T cells. Monkeys immunized with plasmid DNA or an adenoviral vector expressing HPV16L1 showed strong Th1/Tc1 responses as measured by IFN-gamma production by CD4+ and/or CD8+ T cells and potent Immoral responses, but only weakly neutralizing antibodies. These data demonstrate that the nature of the immune response against HPV16L1 is dramatically different when it is introduced via different delivery systems. Additionally, these findings support the notion that an HPV16L1 VLP-based vaccine will induce the strongly neutralizing antibodies necessary for effective prophylaxis. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1539 / 1547
页数:9
相关论文
共 61 条
  • [1] Bontkes HJ, 2000, INT J CANCER, V88, P92, DOI 10.1002/1097-0215(20001001)88:1&lt
  • [2] 92::AID-IJC15&gt
  • [3] 3.0.CO
  • [4] 2-E
  • [5] PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE
    BOSCH, FX
    MANOS, MM
    MUNOZ, N
    SHERMAN, M
    JANSEN, AM
    PETO, J
    SCHIFFMAN, MH
    MORENO, V
    KURMAN, R
    SHAH, KV
    ALIHONOU, E
    BAYO, S
    MOKHTAR, HC
    CHICAREON, S
    DAUDT, A
    DELOSRIOS, E
    GHADIRIAN, P
    KITINYA, JN
    KOULIBALY, M
    NGELANGEL, C
    TINTORE, LMP
    RIOSDALENZ, JL
    SARJADI
    SCHNEIDER, A
    TAFUR, L
    TEYSSIE, AR
    ROLON, PA
    TORROELLA, M
    TAPIA, AV
    WABINGA, HR
    ZATONSKI, W
    SYLLA, B
    VIZCAINO, P
    MAGNIN, D
    KALDOR, J
    GREER, C
    WHEELER, C
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11): : 796 - 802
  • [6] IMMUNIZATION WITH VIRUS-LIKE PARTICLES FROM COTTONTAIL RABBIT PAPILLOMAVIRUS (CRPV) CAN PROTECT AGAINST EXPERIMENTAL CRPV INFECTION
    BREITBURD, F
    KIRNBAUER, R
    HUBBERT, NL
    NONNENMACHER, B
    TRINDINHDESMARQUET, C
    ORTH, G
    SCHILLER, JT
    LOWY, DR
    [J]. JOURNAL OF VIROLOGY, 1995, 69 (06) : 3959 - 3963
  • [7] Human papillomavirus vaccines
    Breitburd, F
    Coursaget, P
    [J]. SEMINARS IN CANCER BIOLOGY, 1999, 9 (06) : 431 - 445
  • [8] Bryan JT, 1997, J MED VIROL, V53, P185, DOI 10.1002/(SICI)1096-9071(199711)53:3<185::AID-JMV1>3.0.CO
  • [9] 2-4
  • [10] Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus
    Christensen, ND
    Reed, CA
    Cladel, NM
    Han, R
    Kreider, JW
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (02) : 960 - 965